Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 15/20 | 0.55 |
| ▸ | AXL | P30530 | 1/20 | 0.45 |
| ▸ | MERTK | Q12866 | 1/20 | 0.45 |
| ▸ | FNTA | P49354 | 1/20 | 0.42 |
| ▸ | FNTB | P49356 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19723168 | 1.00 | PDPK1 (0.55) | PDPK1AXLMERTKFNTAFNTB | |
| SCHEMBL2621682 | 1.00 | PDPK1 (0.55) | PDPK1AXLMERTKFNTAFNTB | |
| SCHEMBL12182677 | 0.90 | PDPK1 (0.51) | PDPK1AXLMERTKFNTAFNTB | |
| SCHEMBL12183016 | 0.88 | PDPK1 (0.45) | PDPK1AXLMERTK | |
| SCHEMBL19723197 | 0.87 | PDPK1 (0.54) | PDPK1 | |
| SCHEMBL2621684 | 0.87 | PDPK1 (0.54) | PDPK1 | |
| SCHEMBL2621713 | 0.86 | PDPK1 (0.49) | PDPK1 | |
| SCHEMBL19723194 | 0.86 | PDPK1 (0.51) | PDPK1FNTAFNTBBRD4KDM5B | |
| SCHEMBL2621681 | 0.86 | PDPK1 (0.51) | PDPK1FNTAFNTBBRD4KDM5B | |
| SCHEMBL2621680 | 0.86 | PDPK1 (0.51) | PDPK1FNTAFNTBBRD4KDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560967-B1 | Heterocyclic carboxylic acid amides as PDK1 inihibitors | BOEHRINGER INGELHEIM INT (DE) | 2017-12-20 | — | — | EP | disclosed |
| US-8895581-B2 | 1H-imidazo[4,5-c]quinolines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-25 | — | — | US | disclosed |
| US-8895581-B2 | 1H-imidazo[4,5-c]quinolines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-25 | — | — | US | disclosed |
| US-8575203-B2 | Chemical compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-05 | — | — | US | disclosed |
| US-8575203-B2 | Chemical compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-05 | — | — | US | disclosed |
| US-20130210832-A1 | 1H-IMIDAZO[4,5-C]QUINOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-15 | — | — | US | disclosed |
| US-20130210832-A1 | 1H-IMIDAZO[4,5-C]QUINOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-15 | — | — | US | disclosed |
| US-20120094976-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
| US-20120094976-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
| WO-2011144622-A1 | 1H - IMIDAZO [4, 5 - C] QUINOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-24 | — | — | WO | disclosed |
| WO-2011131741-A1 | HETEROCYCLIC CARBOXYLIC ACID AMIDES AS PDK1 INIHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094976-A1 | NEW CHEMICAL COMPOUNDS | CCNB1, MKI67, CCNA1 | PDPK1 1873/4885AXL 4582/4885MERTK 3938/4885 |
| US-20130210832-A1 | 1H-IMIDAZO[4,5-C]QUINOLINES | MKI67, CCNA1, CCNB1 | PDPK1 2768/4885AXL 4264/4885MERTK 4120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.